Mosaic schizophrenia: what does the term mean and how does it manifest itself?

In popular and outdated sources, "mosaic schizophrenia" typically refers to a clinical picture in which elements of different symptom clusters are simultaneously present—pronounced delusional ideas and hallucinations, disorganized thinking, negative and cognitive symptoms, and sometimes catatonic phenomena—without the dominance of a single "classical subtype." Today, it is more accurate to call this situation polymorphic symptomatology of schizophrenia. [1]

The subtyping scheme of the International Classification of Diseases, 10th revision, is no longer used in the International Classification of Diseases, 11th revision. Instead of "paranoid," "hebephrenic," and "catatonic" forms, the diagnosis is described by domains, a duration of at least 1 month, and characteristics of episodes and course, with catatonia being allocated to a separate diagnostic chapter. This better reflects the true "mosaic" nature of manifestations in a significant proportion of patients. [2]

It's important to distinguish between a colloquial label and a nosology. "Mosaic schizophrenia" does not denote a specific type of illness and does not require specific treatment different from modern standards for schizophrenia management. Treatment plans are based on the severity of the domains, relapse frequency, comorbidity, and patient preferences. [3]

Historically, Russian psychiatry's notions of a "mosaic" nature of symptoms are largely explained by cultural and methodological traditions in describing mental disorders in the USSR. Modern international criteria offer a more verifiable and reproducible diagnostic framework. [4]

Code according to ICD 10 revision and ICD 11 revision

In the International Classification of Diseases, 10th revision, schizophrenia was coded in block F20 with subtypes, but there was no specific code for the "mosaic" form. In clinical practice, clarifications based on the current state and course were used, but the evidentiary value of subtypes proved to be limited. [5]

In the International Classification of Diseases, 11th revision, schizophrenia is coded 6A20. The diagnosis requires at least one month of persistent symptoms, with the description including domains of disturbances in thinking, perception, self-perception, affect, volition, and behavior. Subtypes have been abolished, assessment is based on episodes and course, and delusional disorder is listed separately under code 6A24. [6]

Table 1. How a “mosaic” clinic is coded in modern classifiers

Situation	International Classification of Diseases, 10th revision	International Classification of Diseases, 11th revision
Schizophrenia with polymorphic symptoms	F20.x according to the leading clinical description, without a separate "mosaic" code	6A20 "Schizophrenia" with indication of domains, episode and course
Predominantly stable thematic delirium with the preservation of other areas	F22 "Delusional disorder"	6A24 "Delusional disorder" with a duration of at least 3 months
Catatonic signs in different nosologies	F20.2 in the old subtyping logic	A separate subchapter "Catatonia" in the spectrum of disorders

[7]

Epidemiology

The global prevalence of schizophrenia, according to current estimates, is approximately 0.33–0.75% of the population. This corresponds to tens of millions of people worldwide and constitutes a significant proportion of the global disease burden. A polymorphic, "mosaic" picture is common, as the domain profiles in most patients are mixed. [8]

According to global burden of disease analyses, the absolute number of patients has increased since the early 1990s, driven by population growth and improved detection. However, disability rates remain stably high, highlighting the need for early diagnosis and comprehensive care. [9]

The age of onset is typically between 15 and 35 years. Men, on average, begin to develop the disease earlier than women, and urbanization is associated with an increased risk. These factors do not create a specific "mosaic" pattern, but they do explain the diversity of presentations among different groups. [10]

Excess mortality in people with schizophrenia is due to cardiometabolic diseases and suicide risk. Timely treatment and prevention of metabolic complications reduce this gap and improve survival. [11]

Reasons

The etiology is multifactorial. Heritability is high, and contributions are determined by hundreds of polygenic variants and rare mutations affecting neurotransmitter and neurodevelopmental pathways. Polymorphic symptoms are expected given such biological heterogeneity. [12]

Environmental factors modify risk. The most consistent association has been shown for frequent use of high-potency cannabis, particularly during adolescence, with increased odds of psychosis and more severe episodes. This is not a "cause" per se, but it significantly increases risk in vulnerable individuals. [13]

Perinatal complications, infections, and childhood trauma also increase the risk of developing the disease, but their contribution varies from person to person. Together, these factors create a "mosaic" predisposition profile, which can later manifest itself in similarly "mosaic" clinical manifestations. [14]

Finally, social factors, including urbanization and migration, are associated with the risk of psychosis. Mechanisms include chronic stress and social isolation, which increase the severity of individual symptom domains in predisposed individuals. [15]

Risk factors

A family history of psychosis and an early age of onset in first-degree relatives increase the risk. This does not predict outcome, but it does dictate attention to early signs and the prevention of triggers. [16]

Adolescence and frequent use of high-potency cannabis are statistically associated with earlier onset and more severe disease. Cannabis abstinence is an important part of secondary prevention. [17]

Perinatal exposures and urbanization increase the likelihood of disease at the population level, although individual predictions based on a single factor are impossible. These data help design public health measures. [18]

Comorbid anxiety disorders, sleep disorders, and other substance use are associated with more frequent relapses and a more "mosaic" clinical picture, as they exacerbate different symptom domains. Managing these conditions is part of the basic strategy. [19]

Table 2. Risk factors and nature of evidence

Factor	Level and nature of communication	Commentary for practice
Family history of psychosis	Robust population data	Early recognition of symptoms and family support
High-potency cannabis	Meta-analyses and European reports confirm the risk	Quitting cannabis is especially important for teenagers
Perinatal and early stress	Associative data	Impossibility of individual forecasting based on one factor
Urbanization	Population associations	The influence of social determinants
Chronic sleep deprivation	Flow modifier	Sleep correction reduces relapses

[20]

Pathogenesis

The leading role is played by imbalances in dopaminergic transmission with hyperactivity of the mesolimbic pathway and relative hypofunction of the prefrontal cortex, which explains the association of positive symptoms with impaired motivation and cognitive deficits. Polymodal impairments lead to a "mosaic" of phenomena. [21]

The glutamate and N-methyl-D-aspartate receptor systems are also involved, explaining the persistence of negative and cognitive symptoms. The combination of dopaminergic and glutamatergic mechanisms produces variable profiles in different individuals. [22]

The neurodevelopmental model emphasizes early disruptions in brain network organization. These differences become apparent during adolescence, when stress and hormonal factors increase vulnerability. This is consistent with the heterogeneous clinical presentation. [23]

The contribution of inflammatory and metabolic pathways partly explains the higher somatic morbidity and variable response to therapy, which is important to consider when choosing treatment and monitoring strategies. [24]

Symptoms

Positive symptoms include delusions, hallucinations, and disorganized thinking and behavior. They often predominate during exacerbations, but their combinations vary from patient to patient, forming a "mosaic" pattern. [25]

Negative symptoms—apathy, avolition, speech impoverishment, and emotional flattening—are usually more persistent and determine the level of functioning between episodes. Their presence creates a need for long-term support. [26]

Cognitive impairments affect attention, memory, and social cognition. They are closely associated with learning and employment difficulties and require targeted rehabilitation programs. [27]

Catatonic phenomena are possible within various nosologies, and are considered in a separate subchapter in the International Classification of Diseases, 11th revision. Their recognition is critical, since some treatment methods are specific. [28]

Table 3. Symptom domains in schizophrenia according to the International Classification of Diseases, 11th revision

Domain	Examples of manifestations	Practical significance
Thinking	Delirium, incoherence, neologisms	Determines the need for antipsychotics
Perception	Auditory hallucinations	Often a marker of exacerbation
Self-perception	A sense of external control	Associated with risk of distress
Motivation and will	Avolition, apathy	The key to rehabilitation and support
Affect	Emotional flattening	Affects social participation
Behavior	Disorganization, catatonia	Security risks and urgency of assistance
Cognitions	Impaired attention and memory	Predictor of employment

[29]

Classification, forms and stages

The subtyping scheme of the International Classification of Diseases, 10th revision, has been replaced by the hybrid categorical-dimensional approach of the International Classification of Diseases, 11th revision. The diagnosis captures the presence of schizophrenia and describes the severity of domains, the current episode, and the course of the disorder, without subtyping "by form." This reflects the true heterogeneity and "mosaic" nature of the clinical picture. [30]

Delusional disorder has its own code, 6A24, and is characterized by persistent thematic delusional ideas with relative preservation of other areas of the psyche and a duration of at least 3 months. It is important not to confuse it with schizophrenia, which has a partially "mosaic" picture. [31]

Catatonia is classified in a separate subchapter and can occur in a variety of disorders, including schizophrenia, affective disorders, and medical conditions. Proper classification determines the choice of treatment methods, such as the need for lorazepam or electroconvulsive therapy for strict indications. [32]

In the clinic, it is convenient to talk about the first episode of psychosis, multiple episodes with remissions, or a continuous course. This language facilitates joint treatment and rehabilitation planning, as well as communication between specialists. [33]

Complications and consequences

Untreated relapses worsen negative and cognitive symptoms, impairing autonomy and quality of life. Early access to care and supportive therapy reduce the burden of illness. [34]

Cardiometabolic complications are more common than in the general population, both due to the disease and some medications. Active monitoring of body weight, waist circumference, glucose, and lipids is required. [35]

Suicide risk is increased, particularly in the early years of illness and with comorbid depression and substance use. A safety plan and relapse prevention are essential to reduce these risks. [36]

Social consequences include interrupted education, loss of employment, and stigma. Rehabilitation programs and supported employment significantly improve long-term outcomes. [37]

When to see a doctor

Seek immediate help if you experience hearing voices, persistent delusional beliefs, severe suspiciousness, disorganized behavior, suicidal thoughts, or a threat to your safety. Early intervention is associated with better outcomes. [38]

Acute catatonic symptoms, severe insomnia, severe anxiety with risk of self-harm, and a sharp decline in daily functioning warrant urgent evaluation. These conditions require immediate treatment. [39]

Relatives are encouraged to record changes in sleep, interests, communication, and performance, as external observations help the doctor assess progress and plan care. This is especially important during the initial consultation. [40]

Even if in doubt, it's best to discuss your complaints with a general practitioner or psychiatrist to shorten the duration of untreated psychosis. This reduces the risk of relapse and disability. [41]

Diagnostics

The initial stage is a detailed clinical psychiatric interview assessing domains, duration of symptoms for at least 1 month for schizophrenia, level of functioning, risk factors, and safety. Substance use, sleep, and stressful events are also examined. [42]

The second stage is to exclude induced and organic causes: physical and neurological examination, basic laboratory tests, thyroid hormones, vitamin B12 and folate, toxicology screening, and, if indicated, infection tests. This reduces the risk of missing reversible causes. [43]

The third stage is instrumental diagnostics as indicated. Electroencephalography is indicated if an epileptic nature of the symptoms is suspected. Neuroimaging is indicated in cases of late onset, neurological deficit, and atypical progression. [44]

The fourth stage involves developing an individualized care and rehabilitation plan, taking into account the patient's domain "mosaic," family and social contexts, goals, and relapse risks. The plan is revised as data accumulates and the patient responds to therapy. [45]

Table 4. Minimum diagnostic kit for suspected schizophrenia

Block	What are we doing?	Why is this necessary?
Clinical and psychiatric assessment	Symptom domains, duration, level of functioning, risks	Confirmation of the criteria of the International Classification of Diseases, 11th revision
Laboratory screening	General and biochemical analysis, thyroid-stimulating hormone, vitamin B12 and folate, toxicology screening	Exclusion of reversible causes and aggravating factors
Instrumental methods	Electroencephalography, neuroimaging as indicated	Distinction from epilepsy and organic pathology
Psychosocial assessment	Needs, resources, goals, barriers	Personalizing your care plan

[46]

Differential diagnosis

Delusional disorder is characterized by persistent thematic delusions with relative preservation of other areas of the psyche and a duration of at least 3 months. With overlapping hallucinations and disorganized thinking, schizophrenia with polymorphic symptoms is more likely. [47]

Schizoaffective disorder is diagnosed when the criteria for schizophrenia are met and a severe affective episode of appropriate duration occurs. In practice, this requires a targeted search for and verification of affective symptoms. [48]

Substance- and medication-induced psychoses are identified based on the association with use and the regression of symptoms after withdrawal. High-potency cannabis increases the risk of psychosis onset and severity, necessitating active screening for use. [49]

Neurological and somatic conditions, including epilepsy, endocrine, and autoimmune diseases, are excluded using laboratory and instrumental methods based on clinical indications. This is crucial in cases of late onset and atypical dynamics. [50]

Table 5. Differences in the main conditions with psychosis

State	Key criterion	What does the diagnosis suggest?
Schizophrenia 6A20	≥ 1 month, 2 or more domains, one positive	Polymodal symptoms and functional decline
Delusional disorder 6A24	≥ 3 months of persistent delirium	Relative preservation of other areas
Schizoaffective disorder	Schizophrenia criteria plus affective episode	Synchronicity and duration of affective symptoms
Induced psychosis	Substance addiction and withdrawal regression	Screening for use, especially cannabis

[51]

Treatment

Antipsychotic pharmacotherapy is the mainstay of treatment. Drug selection is based on the patient's primary domains, tolerability profile, risk of metabolic complications, and preferences. In the initial episode, agents with a more favorable metabolic profile are often selected, and the dose is gradually increased. [52]

If there is insufficient response to two adequate courses of different antipsychotics, clozapine is considered, which remains the most effective for resistant positive symptoms and reduces suicidality, but requires strict monitoring of blood and metabolic parameters. [53]

Long-acting injectable formulations help reduce the risk of relapse and hospitalization, especially in those with poor adherence. The choice of formulation and molecule depends on efficacy and tolerability, as well as patient preference and availability. [54]

Psychotherapeutic and psychosocial interventions include cognitive behavioral therapy for psychosis, family programs, and supported employment. These approaches improve functioning and quality of life, particularly in those with severe negative and cognitive symptoms. [55]

Metabolic management is essential for all patients receiving antipsychotics. Regular monitoring of body weight, waist circumference, fasting glucose, and lipids, and early initiation of non-pharmacological measures and, if indicated, pharmacological correction in the event of weight gain, reduces long-term risks. [56]

Table 6. Brief summary of key treatment areas

Direction	Target	Comment
Antipsychotic therapy	Control of positive symptoms	Individual selection taking into account tolerance
Clozapine in resistance	Reduction of persistent symptoms and suicidal risk	Strict laboratory monitoring is required.
Long-acting injectable forms	Reducing relapses	Useful for low adherence
Psychotherapy and family programs	Improving Functionality	The effect is greater with early initiation.
Metabolic management	Prevention of complications	Weight, glucose, and lipid monitoring on a schedule

[57]

Prevention

Reducing the duration of untreated psychosis through early referral and referral improves long-term outcomes. This is a key modifiable factor, dependent on family and primary care awareness. [58]

Avoiding high-potency cannabis and other psychoactive substances has been shown to reduce the risk of relapse and more severe episodes. This information is especially important for adolescents and young adults. [59]

Normalizing sleep, stress management, and treating comorbid anxiety and depressive disorders reduce the severity of symptom domains and the frequency of exacerbations. These are simple but effective elements of the strategy. [60]

Family psychoeducation and involvement of loved ones reduce the risk of treatment failure and increase adherence to therapy and follow-up. This is especially important in the first year after onset. [61]

Forecast

With modern management, a significant proportion of patients achieve sustained remission or a low-symptom course. The best results are achieved with early initiation of therapy, abstinence from cannabis use, and systemic psychosocial support. [62]

Severe negative and cognitive symptoms, frequent relapses and comorbid addictions worsen outcomes, but their impact can be reduced by long-term injectable forms, rehabilitation and risk factor management. [63]

Metabolic risks are preventable and treatable, reducing the life expectancy gap with the general population. Regular monitoring and lifestyle modifications increase survival expectancy. [64]

In general, the term “mosaic schizophrenia” should be replaced by a precise description of the domains and course of a specific patient, which facilitates care planning and makes the prognosis more specific. [65]

FAQ

What does "mosaic schizophrenia" mean in modern terminology?
It is not a diagnosis, but a colloquial description of the polymorphic symptoms of schizophrenia. The criteria of the International Classification of Diseases, 11th revision, should be used, specifying the domains and course. [66]

Are there specific medications specifically for the "mosaic" form?
No. Treatment selection is based on symptom domains, effects and tolerability, risks of metabolic complications, and patient preference. In cases of resistance, clozapine is considered. [67]

How can you reduce the risk of relapse?
Maintain maintenance therapy, discuss long-term injectable forms if you have difficulty taking them, abstain from cannabis, improve sleep, and engage your family in psychoeducation. [68]

How does schizophrenia differ from delusional disorder?
Schizophrenia typically involves multiple domains of impairment and functional decline for at least 1 month. Delusional disorder is characterized by persistent thematic delusions lasting at least 3 months, with relative preservation of other aspects of the disorder. [69]

Why were subtypes abolished in the International Classification of Diseases, 11th revision?
Because they did not improve the accuracy of prognosis or treatment selection. The domain-based approach more accurately reflects the clinical reality and simplifies communication between specialists. Catatonia is listed separately because it occurs in different disorders. [70]

Table 7. Patient and family information sheet

Situation	What to do now	What to discuss with your doctor
“Voices” or persistent delusional ideas appeared	Request an in-person safety assessment immediately	Start pharmacotherapy and follow-up plan
Frequent treatment failures	Discuss long-term injectable forms	Schedule of visits and monitoring of side effects
Weight gain during therapy	Lifestyle changes, glucose and lipid monitoring	Options for drug correction of metabolic risks
Cannabis use	Stop immediately	Substance Abstinence Support Programs
The family does not understand the diagnosis	Psychoeducation and family meetings	The role of the environment in relapse prevention

[71]